AnaptysBio (NASDAQ:ANAB) Stock Rating Reaffirmed by Wedbush

Wedbush reissued their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $42.00 target price on the biotechnology company’s stock.

A number of other equities analysts have also recently issued reports on the company. JPMorgan Chase & Co. increased their target price on AnaptysBio from $69.00 to $75.00 and gave the stock an overweight rating in a report on Wednesday, August 7th. HC Wainwright reaffirmed a buy rating and set a $55.00 price objective on shares of AnaptysBio in a research note on Wednesday, August 14th. Finally, Truist Financial upped their price target on AnaptysBio from $20.00 to $30.00 and gave the company a hold rating in a research note on Thursday, August 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $51.10.

AnaptysBio Stock Down 2.0 %

NASDAQ:ANAB opened at $31.87 on Thursday. AnaptysBio has a 52-week low of $13.36 and a 52-week high of $41.31. The firm has a market cap of $870.66 million, a P/E ratio of -5.19 and a beta of -0.29. The business’s 50-day moving average price is $35.68 and its 200 day moving average price is $28.16.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The firm had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. Sell-side analysts expect that AnaptysBio will post -6.84 EPS for the current year.

Insider Activity

In other AnaptysBio news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was purchased at an average cost of $36.50 per share, for a total transaction of $9,999,978.00. Following the acquisition, the insider now owns 7,794,996 shares in the company, valued at approximately $284,517,354. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of the firm’s stock in a transaction that occurred on Wednesday, August 14th. The stock was purchased at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the acquisition, the insider now owns 7,794,996 shares in the company, valued at approximately $284,517,354. The disclosure for this purchase can be found here. Insiders sold 33,940 shares of company stock valued at $1,251,836 over the last quarter. 33.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANAB. Allspring Global Investments Holdings LLC purchased a new stake in AnaptysBio during the first quarter valued at about $38,000. Headlands Technologies LLC raised its stake in AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in AnaptysBio by 66.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 2,051 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of AnaptysBio during the first quarter valued at approximately $222,000. Finally, Algert Global LLC raised its stake in shares of AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after purchasing an additional 1,078 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.